SLC7A11 and prostate carcinoma: In prostate cancer, SPOP can inhibit ferroptosis by promoting Jumonji domain-containing 6 (JMJD6) proteasomal degradation, thereby inhibiting the coordinated enhancer‒promoter loop interaction between JMJD6 and ATF4 and suppressing the expression of SLC7A11, a key gene for glutathione biosynthesis, thus promoting ferroptosis [34].